- Home
- / Eli Lilly
Eli Lilly
Stock Price
$544.5
2023-09-28
Market Capitalization
$409.3 B
2023-05-03
Revenue
$28.5 B
FY, 2022
Eli Lilly Summary
Company Summary
- Overview
- Eli Lilly and Company is a company that discovers, develops, manufactures, and markets pharmaceutical products. It offers diabetes and endocrinology, immunology, neuroscience, oncology, and other products. Its products are distributed through wholesalers that serve pharmacies, physicians, and other health care professionals and hospitals.
- Type
- Public
- Status
- Active
- Founded
- 1876
- HQ
- Indianapolis, IN, US | view all locations
- Website
- https://www.lilly.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Anat Ashkenazi, Senior Vice President and Chief Financial Officer
Stephen F. Fry, Senior Vice President, Human Resources and Diversity
Johna L. Norton, Senior Vice President, Global Quality
Operating MetricsView all
Facilities Owned (US), sq. ft.
8.1M
1.2%
FY, 2021
Facilities Owned, sq. ft.
12.8M
1.6%
FY, 2021
Phase I Trials Products
27
FY, 2019
LocationsView all
49 locations detected
Indianapolis, IN HQ
United States
893 Delaware St
Branchburg, NJ
United States
33 Imclone Dr
Cambridge, MA
United States
450 Kendall St
Indianapolis, IN
United States
1223 W Morris St
Indianapolis, IN
United States
1500 S Harding St
New York, NY
United States
450 E 29th St 12th floor
Eli Lilly Financials
Summary Financials
- Revenue (Q2, 2023)
- $8.3B
- Gross profit (Q2, 2023)
- $6.5B
- Net income (Q2, 2023)
- $1.8B
- Cash (Q2, 2023)
- $2.7B
- Enterprise value
- $425.4B